×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. We are committed to safeguarding your information and ensuring the highest standards of data protection. Your trust and privacy are of utmost importance to us.

Empagliflozin may reduce CKD in patients with type 2 diabetes

  218 Views

eMediNexus    05 November 2017

Findings of a post hoc analysis of the EMPA REG OUTCOME trial show that treatment with empagliflozin may reduce chronic kidney disease CKD in patients with type 2 diabetes and established cardiovascular disease. These findings were reported at ASN Kidney Week 2017 in New Orleans

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.